• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.

作者信息

Florek A G, Nardone B, Thareja S, Tran G, Giles F J, West D P

机构信息

Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N. Saint Clair Street, Suite 1600, Chicago, IL, 60611, U.S.A.

Developmental Therapeutics Program, Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine, 676 N. Saint Clair Street, Suite 1600, Chicago, IL, 60611, U.S.A.

出版信息

Br J Dermatol. 2017 Nov;177(5):e220-e221. doi: 10.1111/bjd.15752. Epub 2017 Oct 22.

DOI:10.1111/bjd.15752
PMID:28646575
Abstract
摘要

相似文献

1
Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.恶性肿瘤与优特克单抗：对美国食品药品监督管理局不良事件报告系统和欧盟药品监管机构药物警戒数据库的分析。
Br J Dermatol. 2017 Nov;177(5):e220-e221. doi: 10.1111/bjd.15752. Epub 2017 Oct 22.
2
Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.疑似异维 A 酸相关性炎症性肠病：律师向食品和药物管理局不良事件报告系统的不当报告。
J Am Acad Dermatol. 2013 Sep;69(3):393-8. doi: 10.1016/j.jaad.2013.04.031. Epub 2013 May 14.
3
European pharmacovigilance: an overview of pharmacovigilance inspections.欧洲药物警戒：药物警戒检查概述
Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):711-3. doi: 10.1002/pds.1088.
4
European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?欧洲药物警戒法规：它是否促使了药物警戒检查的实施？
Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):339-40. doi: 10.1002/pds.622.
5
A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.一种基于美国食品药品监督管理局监管行动和上市后不良事件报告的药物警戒信号系统。
Drug Saf. 2016 Jun;39(6):561-75. doi: 10.1007/s40264-016-0409-x.
6
Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.美国食品和药物管理局不良事件数据库中死亡病例的分类错误。
JAMA Intern Med. 2020 Jan 1;180(1):147-148. doi: 10.1001/jamainternmed.2019.4030.
7
[Science, marketing and pharmacovigilance: the example of topical calcineurin inhibitors].
Ann Dermatol Venereol. 2007 Nov;134(11):817-21. doi: 10.1016/s0151-9638(07)92823-9.
8
Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.多发性硬化症中疾病修饰疗法自发报告完整性分析。
Expert Opin Drug Saf. 2021 Jun;20(6):735-740. doi: 10.1080/14740338.2021.1897566. Epub 2021 Mar 11.
9
Apremilast and suicidality - a retrospective analysis of three large databases: the FAERS, EudraVigilance and a large single-centre US patient population.
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e463-e464. doi: 10.1111/jdv.14256. Epub 2017 Apr 26.
10
[Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].[使用优特克单抗治疗期间的药物性间质性肺病（DILD）]
Hautarzt. 2020 Apr;71(4):309-312. doi: 10.1007/s00105-019-04519-9.

引用本文的文献

1
Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis.自身免疫性脑炎中的细胞因子动力学与靶向免疫疗法
Brain Commun. 2022 Aug 20;4(4):fcac196. doi: 10.1093/braincomms/fcac196. eCollection 2022.
2
Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis.优特克单抗诱发一名银屑病关节炎患者患慢性淋巴细胞白血病。
Reumatologia. 2021;59(1):58-61. doi: 10.5114/reum.2021.102618. Epub 2021 Feb 28.
3
A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.一例使用乌司奴单抗治疗银屑病的患者发生霍奇金淋巴瘤的病例报告。
Medicine (Baltimore). 2020 May 22;99(21):e20048. doi: 10.1097/MD.0000000000020048.
4
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.英夫利昔单抗治疗难治性或不耐受性溃疡性结肠炎的临床疗效。
United European Gastroenterol J. 2020 Feb;8(1):91-98. doi: 10.1177/2050640619895361. Epub 2019 Dec 12.
5
Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.炎症性肠病的生物制剂和免疫抑制剂治疗的总体和比较安全性。
Expert Rev Clin Immunol. 2019 Sep;15(9):969-979. doi: 10.1080/1744666X.2019.1646127. Epub 2019 Jul 25.
6
Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?白细胞介素-12 和/或白细胞介素-23 抑制治疗银屑病：对恶性肿瘤有影响的证据是什么？
Exp Dermatol. 2018 Jul;27(7):737-747. doi: 10.1111/exd.13676.